urelumab: Clinical Trials

13 trials of urelumab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 4 terminated, 1 unknown, 1 withdrawn. 13 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 113Completed 7, Terminated 4, Unknown 1, Withdrawn 1
Phase 23Terminated 2, Unknown 1

Follow urelumab: new trials by email Literature Review of urelumab trials Research Report on urelumab

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors
Urelumab + Nivolumab - Neoplasms
Phase 1 / Phase 2UnknownClinica Universidad de Navarra, Universidad de Navarra322019-01-302019-01-03
Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer
Nivolumab, Cabiralizumab, Urelumab - Cancer
Phase 1CompletedUniversity of Chicago602018-03-152023-02-16
Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)
Anti-LAG-3 Monoclonal Antibody BMS 986016, Anti-PD-1, Pharmacological Study - Glioblastoma, Gliosarcoma
Phase 1CompletedSidney Kimmel Comprehensive Cancer Center at Johns Hopkins632016-08-242023-10-06
Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors
Urelumab, Nivolumab - Malignant Tumors
Phase 1CompletedBristol-Myers Squibb182015-11-062020-05-18
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Elotuzumab, Lirilumab, Urelumab - Multiple Myeloma
Phase 1CompletedBristol-Myers Squibb442014-12-092017-11-01
An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma
Urelumab, Nivolumab - Advanced Solid Tumors, Advanced B-cell NHL
Phase 1 / Phase 2TerminatedBristol-Myers Squibb2322014-09-292020-10-05
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
Urelumab, Cetuximab - Colorectal Cancer, Head and Neck Cancer
Phase 1CompletedBristol-Myers Squibb662014-04-012017-04-19
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
Urelumab, Rituximab - B-Cell Malignancies
Phase 1CompletedBristol-Myers Squibb472013-03-012017-03-31
Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Urelumab (BMS-663513) - Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma
Phase 1CompletedBristol-Myers Squibb1242012-02-012017-04-19
Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma
AntiCD137, Ipilimumab - Melanoma
Phase 1WithdrawnBristol-Myers Squibb2010-11-012011-11-21
A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)
BMS-663513 - Non Small Cell Lung Cancer
Phase 1TerminatedBristol-Myers Squibb352008-01-012009-09-04
A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies
BMS-663513 - Advanced Solid Malignancies
Phase 1TerminatedBristol-Myers Squibb452007-09-012009-09-04
Study of BMS-663513 in Patients With Advanced Cancer
BMS-663513 - Tumors
Phase 1 / Phase 2TerminatedBristol-Myers Squibb1152005-12-012015-10-12

Conditions studied

Neoplasms (4)  ·  Brain Neoplasms (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Colorectal Neoplasms (1)  ·  Glioblastoma (1)  ·  Gliosarcoma (1)  ·  Head and Neck Neoplasms (1)  ·  Lymphoma, B-Cell (1)  ·  Melanoma (1)  ·  Multiple Myeloma (1)

Sponsors

Bristol-Myers Squibb (10)  ·  Clinica Universidad de Navarra, Universidad de Navarra (1)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)  ·  University of Chicago (1)

Countries

United States (11)  ·  Spain (4)  ·  France (3)  ·  Canada (2)  ·  Germany (2)  ·  Japan (1)

Top investigators

Jason Luke, MD (1)  ·  Micheal Lim, MD (1)

Results publications

PMID 38458639, PMID 41543348, PMID 42432293

NIH funding

2014 (1), UM1CA137443 (1)